Your Employer Is Dropping GLP-1 Coverage: What to Do Before 2027 Open Enrollment

The 12-point swing landed quietly. In a Business Group on Health survey of about 127 large employers released this summer, the share of companies covering GLP-1 drugs for obesity dropped from 72% in 2025 to 60% in 2026 — a one-year retreat that reversed years of steady expansion. KFF's broader survey tells the same story from the other direction: only about 36% of employers who offer any GLP-1 coverage extend it to weight loss, and the biggest employers (5,000+ workers) sit at just 43%. Whichever number you look at, the trend for the 2027 plan year points one way, and it isn't up.

If Wegovy or Zepbound is on your list, this matters at the exact moment 2027 open enrollment materials start hitting your inbox — typically mid-October through mid-November for employer plans. Coverage that existed in 2026 may not exist in 2027, and the change is easy to miss if you skim the Summary of Benefits and Coverage. Here's what's actually changing, how to read your plan documents for it, and what your options are if the drug you rely on falls off the formulary.

The math is what changed, not the medicine. GLP-1 drugs work — the clinical trial results for Wegovy and Zepbound remain some of the most convincing weight-loss data anyone has ever published. But list prices run roughly $1,000 to $1,350 per month, uptake has been higher than anyone modeled, and long-term use is the norm rather than the exception. Put those three facts together and GLP-1s can consume 10% to 20% of a mid-size employer's entire drug budget within eighteen months of adding coverage.

Employers respond in three ways. Some narrow the eligibility — higher BMI thresholds, mandatory participation in a lifestyle program, or step therapy that requires trying older weight-loss drugs first. Some keep coverage but move GLP-1s to the specialty tier with 30% coinsurance, which shifts a big chunk of the cost back to the employee. And an increasing number simply drop the weight-loss indication for 2027 while keeping the diabetes indication in place. That last change is the one people miss, because Ozempic and Wegovy contain the same molecule (semaglutide) but are approved for different uses at different doses.

Employer open enrollment materials arrive in a bundle: a Summary of Benefits and Coverage (SBC), a formulary, and a set of announcements about “benefit changes for 2027.” The GLP-1 status doesn't always show up in the highlights. Here's where to actually look:

1. The formulary, filtered by drug name. Search for “Wegovy,” “Zepbound,” “Saxenda,” and “Contrave.” If they're listed with a tier and a copay, they're covered. If they're marked “NF” (non-formulary), “excluded,” or missing entirely, the plan doesn't cover them next year.
2. The prior authorization criteria. Many plans still list Wegovy on the formulary but require a specific BMI, a documented failed weight-loss attempt, or participation in a coaching program. Read the PA sheet, not just the tier number.
3. The specialty pharmacy carve-out. Some plans move GLP-1s to a specialty tier with coinsurance rather than a copay. A drug that used to cost you $50 a month can cost you $300 a month at 30% coinsurance without technically being “dropped.”
4. Any exclusion list. Look for a section titled “Excluded services and drugs” or “What's not covered.” A blanket exclusion of “drugs for weight loss” is the version employers most often use, and it captures Wegovy and Zepbound whether or not they appear on the formulary.

1. Switch to the diabetes-indicated brand if you qualify

Ozempic (semaglutide) and Mounjaro (tirzepatide) are the diabetes-indicated versions of Wegovy and Zepbound. Same active ingredients, slightly different doses. If you have a Type 2 diabetes diagnosis — or if a workup shows one you didn't know about — your prescriber can write for the diabetes brand with the appropriate diagnosis code, and coverage typically follows. This is the single biggest lever, and it's why the diabetes indication has held up while the obesity indication has been cut.

2. Direct-from-manufacturer cash programs

Both makers now sell direct to self-pay patients at prices well below the list. Eli Lilly's LillyDirect ships Zepbound in single-dose vials at roughly $349 to $499 per month depending on the dose. Novo Nordisk's NovoCare Pharmacy offers a similar direct program for Wegovy in the same rough range. These aren't insurance, so they don't count toward your deductible or out-of-pocket max — but they cut the sticker price by more than half.

3. Manufacturer copay cards, if you still have partial coverage

If your plan covers Wegovy or Zepbound but at a punitive specialty tier, the manufacturer's copay card can bring your monthly cost down to around $25 for a limited stretch (typically 12 to 13 months). Copay cards work only with commercial insurance — not Medicare, Medicaid, or Tricare — and they're structured to help through the deductible phase, not indefinitely.

4. HSA or FSA dollars on top of any option

Whatever you pay for a GLP-1 prescribed for a diagnosed condition, you can pay it with pre-tax HSA or FSA money. At a 24% federal marginal rate plus 6% state, that's roughly a 30% discount layered on top of whatever price you found. In 2026 the HSA contribution limits are $4,400 for self-only coverage and $8,750 for family coverage, with a $1,000 catch-up if you're 55 or older; the 2027 limits rise to $4,500 and $9,000.

5. Compounded versions (with more caveats than before)

Compounded semaglutide and tirzepatide were widely available in 2024 and early 2025 while the FDA had declared shortages. Those declarations ended in 2024 (tirzepatide) and 2025 (semaglutide), and enforcement against compounding pharmacies has tightened. Compounded product is still out there but the legal and quality picture has narrowed. If you go this route, use a state-licensed compounding pharmacy that publishes third-party testing, and understand that the FDA has not evaluated compounded versions for safety, effectiveness, or quality.

Prices reflect published rates as of September 2026 and vary by dose, plan design, and pharmacy. Use the Drug Cost Finder to check what a specific pharmacy will charge for your dose.

Marketplace plans have never been generous with weight-loss drugs. Most Marketplace formularies still exclude the obesity indication for GLP-1s outright, and that hasn't budged much for 2027. If your employer plan is dropping coverage and you're weighing whether to shop the Marketplace during ACA open enrollment (November 1, 2026 through January 15, 2027), don't assume a Marketplace plan will pick up what your employer plan drops. Check the formulary and any exclusion of “drugs for weight management” before you switch, and use the subsidy calculator to see what a plan that does cover it would actually cost.

Medicare Part D is barred by statute from covering drugs used for weight loss alone — that's a longstanding rule, not a 2026 change. Coverage kicks in when the same drug is prescribed for a Part D-eligible indication: Type 2 diabetes for Ozempic and Mounjaro, cardiovascular risk reduction for Wegovy in patients with established heart disease, and obstructive sleep apnea for Zepbound following its 2024 indication expansion. If your Part D plan denies a GLP-1 written for a covered indication, the appeal process runs through your plan's formulary exception procedure, and a favorable decision typically covers you for the plan year.

1. Confirm your 2027 formulary status. Search your plan's drug list for the specific brand and dose you take, or call the number on your insurance card and ask directly whether it's covered for 2027 and under what conditions.
2. Ask your prescriber about diagnosis codes. If a covered indication (diabetes, cardiovascular disease, sleep apnea) applies to you, a corrected prescription written to that indication may keep coverage in place. Do this with a clinician — not by asking them to write a code that doesn't fit.
3. Price the direct cash program for your dose. Note the price and lead time. Both LillyDirect and NovoCare ship, so factor in the extra week if you're at the end of a prescription.
4. Compare plans if you have a choice. If your employer offers more than one option, or if you're considering an ACA Marketplace plan, run the numbers with a real prescription cost in the model, not the sticker premium alone.
5. Fund an HSA or FSA at open enrollment. Election choices for 2027 close when open enrollment closes. If you'll be paying cash or coinsurance, elect enough to cover it and take the tax discount.
6. Plan the transition with your prescriber if you're stopping. Do this before your last covered fill, not after. A slow taper and a documented weight-maintenance plan are worth setting up early.

The employer retreat from GLP-1 coverage is a real trend, and it's likely to keep going for at least the 2027 plan year while the direct-from-manufacturer programs and generic-tirzepatide dates (still several years out) reshape the market. But “my plan dropped it” and “I can't afford it” aren't the same sentence anymore. Between diabetes-indicated brands where clinically appropriate, direct manufacturer pricing at a third of list, HSA and FSA tax leverage, and a properly filed appeal when a denial doesn't match your diagnosis, the answer for most patients is a stack of partial discounts rather than a single price cut. Take an hour before your open enrollment window closes and put that stack together.